Immunotherapeutic Vaccine Candidate Fast Tracked for Alzheimer Disease
UB-311 is an immunotherapeutic vaccine candidate that targets toxic forms of aggregated amyloid beta in the brain.
UB-311 is an immunotherapeutic vaccine candidate that targets toxic forms of aggregated amyloid beta in the brain.
The approval was based on data from a phase 3 study that included 175 adults with generalized myasthenia gravis who were not previously treated with a complement inhibitor.
In preclinical studies, PRX012 has been shown to bind to beta amyloid plaques and oligomers with high affinity.
PXL770 is a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator.
The long-term extension phase of the phase 3 EMERGE and ENGAGE trials evaluated the efficacy and safety of aducanumab-avwa in adults aged 50 to 85 years with early Alzheimer disease.
Adlarity is a once-weekly transdermal formulation of donepezil that is designed to be worn for 7 days with consistent adhesion.
Acadia Pharmaceuticals resubmitted the sNDA after addressing issues raised in a Complete Response Letter issued by the Agency.
The Cionic Neural Sleeve is the first product to combine movement analysis and augmentation into a wearable garment.
The IGIV and IGSC products were voluntarily withdrawn due to a higher rate of allergic/hypersensitivity type reactions, some of which were considered medically significant.
SPN-830 provides a continuous subcutaneous infusion of apomorphine through an infusion pump.